JNJ vs NVS
Johnson & Johnson and Novartis AG, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | JNJ | NVS |
|---|---|---|
| Revenue | $94.2B | $54.5B |
| Net income | $26.8B | $14.0B |
| Gross margin | 67.9% | 78.8% |
| Net margin | 28.5% | 25.6% |
| Return on equity | 35.0% | 31.0% |
| Diluted EPS | $11.03 | $7.15 |
| Dividend / share | $5.14 | · |
| Payout ratio | · | · |
| Free cash flow | $19.7B | $17.6B |
| Equity | · | $46.1B |
| Net debt / equity | 0.27× | 0.37× |
| Current ratio | 1.03× | 1.12× |
| Revenue CAGR 5y | 2.7% | 2.3% |
| Profit CAGR 5y | 12.7% | 11.6% |
JNJ bills 1.7× the revenue of NVS, and keeps more of each dollar of revenue as profit (28.5% against 25.6%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | JNJ | NVS |
|---|---|---|
| FY2025 | $94.2B | $54.5B |
| FY2024 | $88.8B | $50.3B |
| FY2023 | $85.2B | $45.4B |
| FY2022 | $80.0B | $42.2B |
| FY2021 | $78.7B | $42.8B |
| FY2020 | $82.6B | $48.7B |
| FY2019 | $82.1B | $47.5B |
| FY2018 | $81.6B | $44.8B |
| FY2017 | $76.5B | $42.4B |
| FY2016 | $71.9B | $48.5B |
Bottom line
| Fiscal year | JNJ | NVS |
|---|---|---|
| FY2025 | $26.8B | $14.0B |
| FY2024 | $14.1B | $11.9B |
| FY2023 | $35.2B | $14.8B |
| FY2022 | $17.9B | $7.0B |
| FY2021 | $20.9B | $24.0B |
| FY2020 | $14.7B | $8.1B |
| FY2019 | $15.1B | $11.7B |
| FY2018 | $15.3B | $12.6B |
| FY2017 | $1.3B | $7.7B |
| FY2016 | $16.5B | $6.7B |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$39,661,000,000 | JNJ |
| FY2024 | +$38,504,000,000 | JNJ |
| FY2023 | +$39,719,000,000 | JNJ |
| FY2022 | +$37,784,000,000 | JNJ |
| FY2021 | +$35,959,000,000 | JNJ |
| FY2020 | +$33,925,000,000 | JNJ |
| FY2019 | +$34,561,000,000 | JNJ |
| FY2018 | +$36,748,000,000 | JNJ |
| FY2017 | +$34,069,000,000 | JNJ |
| FY2016 | +$23,372,000,000 | JNJ |
JNJ has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +2.8 pp | JNJ |
| FY2024 | −7.9 pp | NVS |
| FY2023 | +8.6 pp | JNJ |
| FY2022 | +6.0 pp | JNJ |
| FY2021 | −29.6 pp | NVS |
| FY2020 | +1.2 pp | JNJ |
| FY2019 | −6.3 pp | NVS |
| FY2018 | −9.4 pp | NVS |
| FY2017 | −16.5 pp | NVS |
| FY2016 | +9.2 pp | JNJ |
The higher net margin has changed hands between JNJ and NVS over this period.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NVS's net margin has been more volatile than JNJ's over the 10 comparable fiscal years — 11.6 percentage points of standard deviation against 9.6.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between JNJ and NVS over these 10 fiscal years — JNJ led in 5 and NVS in 5.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
JNJ's return on equity has been more volatile than NVS's over the 10 comparable fiscal years — 11.1 percentage points of standard deviation against 9.6.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between JNJ and NVS over these 10 fiscal years — JNJ led in 7 and NVS in 3.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.